Thompson Scientific released its quarterly review of scientific literature on drugs and therapies and Novartis appears to have taken the lead form GlaxoSmithKline. The report takes an objective look at the quantity and quality of scientific literature published by pharmaceutical companies and other research institutions.
The ranking includes a recognition score and so the list is as follows:
- Novartis AG (NYSE:NVS) - 82 articles
- AstraZeneca's (NYSE:AZN) - 67 articles
- Eli Lilly & Co. (NYSE:LLY) - 62 articles
- GlaxoSmithKline's (NYSE:GSK) -64 articles
- Bristol-Myers Squibb (NYSE:BMY) - 64 articles
- Pfizer Inc. ( NYSE:PFE) - 55 articles
- National Institute of Health - 43 articles
- Merck & Co. (NYSE:MRK) - 34 articles
- Janssen-Cilag - 33 articles
- sanofi-aventis (EPA:SAN)- 34 articles
- Novo Nordisk (NYSE:NVO)- 16 articles
- Takeda (TYO:4502)- 18 articles
- National Institute of Mental Health - 16 articles
- Boehringer Ingelheim - 16 articles
- Abbott Laboratories' (NYSE:ABT) - 16 articles
The commentary at the end of the announcement included the comment: "We continue to observe the generally robust nature of the scientific materials published in the leading information resources that healthcare professionals read. Our analyses continue to find that many pharmaceutical companies have good grounds for saying what they say, and say it well.”
To read the entire article and understand the methodology behind the rankings check out the Thompson Scientific report.
Comment Preview